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INTRODUCTION 
                      Esophageal cancer is unique among the gastrointestinal tract 
malignancies because it embodies two distinct histopathologic types, squamous 
cell carcinoma and adenocarcinoma. In  2008,  an estimated  16,470 people  in the  
United  States  were  told  that  they  have esophageal carcinoma1.  During the 
same year, an estimated 14,280 people died of this disease1. This high rate of 
mortality occurs even though the esophagus is in a relatively  accessible  location  
and  the  use  of  screening  endoscopy  is  widespread.   
                     One reason for the high mortality is the difficulty in properly 
identifying and treating early lesions. Which type of cancer occurs in a given 
patient or predominates in a given geographic area depends on many variables, 
including individual lifestyle, socioeconomic pressures, and environmental 
factors. The United States, along with many other Western countries, has 
witnessed in recent decades a profound increase in incidence rates of 
adenocarcinoma, whereas squamous cell carcinoma continues to predominate 
worldwide.  
                      Although it would seem appropriate to individualize treatment of 
these tumors, often they are managed as a single entity. Present-day therapeutic 
interventions have had limited impact on survival, as evidenced by the case 
fatality rate of 90%. However, a more thorough understanding of the initiating 
events, the molecular biologic basis, and treatment successes and failures has 
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begun to spawn a new era of therapy aimed at targeting both adenocarcinoma 
and squamous cell carcinoma of the esophagus. 
 
                      At the department of Medical Oncology, Madras Medical College, 
Chennai, we register about 2200-3000 new patents annually. Of these, nearly 4-
6% cancers are those, which involve the esophagus as their primary site. Most of 
the cancers are Squamous cell carcinomas, while Adenocarcinomas have been 
showing a steady increase over the past few decades.   
 
                      Natural history data and patterns of failure after specific treatment 
modalities provide insight into the biologic behavior of esophageal carcinoma 
and suggest potential therapeutic avenues to explore. At presentation, the 
overwhelming majority of patients have locally or regionally advanced or 
disseminated cancer, irrespective of histologic type1,2.  
 
                     The lack of a serosal envelope and the rich submucosal lymphatic 
network of the esophagus provide a favorable milieu for extensive local 
infiltration by tumor and lymph node involvement. If distant disease is not 
clinically evident at the time that patients are initially diagnosed with esophageal 
carcinoma, evidence suggests that occult micrometastases are invariably present, 
and recurrence patterns confirm that distant failure is a significant and 
universally fatal component of relapse3,4,5,6,7. 
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                      While patients diagnosed with a deeply invasive carcinoma are 
usually treated with chemotherapy and radiation followed by surgery, many 
patients with early lesions are today managed endoscopically.  
                      Median survival after esophagectomy for patients with localized 
disease is 15 to 18 months with a 5-year overall survival rate of 20% to 25%. 
Patterns of failure after esophagectomy suggest that both location of tumor and 
histologic type may influence the distribution of recurrence. In patients with 
cancers of the upper and middle thirds of the esophagus, which are 
predominately squamous cell carcinomas, locoregional recurrence predominates 
over distant recurrence, whereas in patients with lesions of the lower third, 
where adenocarcinomas are more frequently located, distant recurrence is more 
common3,4. The addition of chemotherapy, radiotherapy, or chemoradiotherapy 
to surgery may alter patterns of failure, although reported results are not 
consistent. 
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REVIEW OF LITERATURE 
                     Optimal treatment of esophageal cancer in every major stage 
grouping (premalignant or intramucosal lesions, localized resectable tumors, and 
unresectable metastatic disease) remains elusive and a work in progress that 
continues to engender substantial controversy. The paucity of appropriately 
designed studies to scientifically determine the most effective therapeutic 
strategy for any given clinical situation fuels the ongoing debate and undermines 
the potential for achieving consensus. Although there is no disagreement that 
esophageal resection prevents progression from high-grade dysplasia to invasive 
carcinoma and is curative for T1 lesions limited to the mucosa, the morbidity and 
mortality associated with esophagectomy has created enthusiasm for alternative 
approaches such as mucosal ablation and endoscopic resection. Surgery has 
always been considered the most effective way of ensuring both locoregional 
control and long-term survival for patients with tumors invading into or beyond 
the submucosa with or without lymph node involvement. Some investigators 
suggest that extending the limits of resection will further improve outcome. 
However, surgery alone or any other single modality fails in most patients, 
which has led many oncologists to embrace combined modality therapy and 
some to question the necessity for surgical intervention. Chemoradiotherapy 
with or without resection is the most common therapeutic regimen offered to 
patients with esophageal carcinoma in the United States2.  A full understanding 
of these issues and others regarding the treatment of carcinoma of the esophagus 
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requires careful scrutiny of the available literature with an attempt to separate 
bias from fact in developing a rational therapeutic approach for patients 
regardless of the stage of their disease. Here, we shall discuss the role of 
chemotherapy, especially cisplatin based regimens, in both locally advanced and 
metastatic esophageal carcinoma. 
 
CHEMOTHERAPY IN LOCALLY ADVANCED DISEASE 
 
                     For locally advanced esophageal cancer, surgery remains the 
mainstay of treatment. Various reviews have reported 5-year overall 
survival(OS) rates from 10% up to 30% to 40% with surgical resection alone8,9. 
Primary radiation therapy previously was used for local tumor control, although 
less successfully. In one large series, the 3-year survival after radiotherapy alone 
was only 6%8. For metastatic disease, chemotherapy alone results in response 
rates of only 20% to 40% and median survivals of 8 to 10 months9. 
 
                      Given the activity of all three modalities, numerous studies have 
combined them in Distinct neoadjuvant(preoperative) strategies for locally 
advanced disease. Multimodality approaches have included chemotherapy or 
concurrent chemoradiotherapy followed by surgery or definitive 
chemoradiotherapy, in an effort to improve the dismal prognosis of this 
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aggressive cancer. Relatively few studies have focused on an adjuvant 
(postoperative) approach. 
 
                     The results of these studies have been mixed, and their combined 
outcomes have failed to elevate any preoperative strategies to a clear standard 
for resectable esophageal cancer. Recent trials involving preoperative 
chemoradiotherapy and pre- and peri-operative  chemotherapy,  however,  have  
demonstrated  improved  survival over surgery alone. Based on these data, many 
clinicians now treat locoregional disease with preoperative multimodality 
therapy. 
 
A. NEOADJUVANT CHEMOTHERAPY  
 
                      Despite  the  short-lived  responses  using  chemotherapy  alone  in  
advanced  disease, neoadjuvant chemotherapy is associated with many 
theoretical benefits10. This approach  has  the  potential  to  assess  tumor  
response  to  chemotherapy  and  direct the possible use of chemotherapy 
postoperatively. Chemotherapy also may improve baseline dysphagia, 
downstage the primary tumor, and increase resection rates and treat 
micrometastatic disease that is undetectable at diagnosis. Kok and colleagues11  
reported a small randomized phase three trial, in which 148 patients who had 
SCC were randomized to surgery alone or preoperative cisplatin/ etoposide 
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followed by surgery. Preoperative chemotherapy was associated with a 
significant improvement in median OS (18.5 months versus 11 months). No final 
report of this study has been published.  
 
                      The large North American Intergroup 113 trial, however, failed to 
show a survival benefit  for  peri-operative  cisplatin/5-fluorouracil  (5-FU)  plus  
surgery compared with surgery alone in 440 patients who had adenocarcinoma 
and squamous cell carcinoma12. Patients  in  the  combined-modality  arm  
received  three  cycles  of  cisplatin/5-FU preoperatively and two cycles 
postoperatively. Pathologic complete responses (pCR) were seen in only 2.5% of 
patients receiving preoperative chemotherapy, and there  was  no  improvement  
in  the  curative  resection  rate.  The  median  OS was not significantly  different 
in the two groups, and the 5-year OS with or without chemotherapy was 20%. 
The addition of chemotherapy did not change the rate of recurrence either  
locally  or  at  distant  sites. Outcome also did not differ by histology, with no 
benefit seen for preoperative chemotherapy for either adenocarcinoma or SCC. 
 
                     Renewed interest in preoperative chemotherapy was generated by a 
trial performed by the Medical  Research Council  Esophageal  Cancer  Working  
Group13. This study randomized 802 patients (nearly double the number of 
patients in the Intergroup trial) to surgery alone versus two cycles of 
preoperative cisplatin/5-FU. At a relatively short median  follow-up  of  only  2  
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years,  the  chemotherapy-treated  group demonstrated improved  median  OS  
(16.8  months  versus  13.3  months)  and  2-year  survival (43% versus   34%). The 
curative resection rate was improved marginally from 55% to 60%,  and  the  
pCR  rate  was  4%  in  the  preoperative  therapy  group.  Mature results of this 
trial recently were updated in abstract form14. At 5 years, there continued to be a 
statistically significant but numerically smaller OS benefit for preoperative 
therapy (23% versus 17%). The trial reported a sobering operative mortality rate 
of 10%.  
 
                     It may be that the larger sample size compared with the Intergroup 
trial facilitated the detection of a small improvement with chemotherapy. In 
addition, a larger proportion of patients on this trial had adenocarcinoma 
histology compared with the Intergroup  113  trial  (66%  versus  54%).  Two  
recent  meta-analyses  (described  in detail) suggest  a  potentially  greater  
survival  benefit  from  preoperative  chemotherapy for patients who have 
adenocarcinoma versus SCC15,16. 
 
                      Additional evidence to support the use of peri-operative 
chemotherapy comes from the recent Medical Research Council Adjuvant Gastric 
Infusional Chemotherapy (MAGIC) trial performed in the United Kingdom17. 
This trial randomized 503 patients who had gastric or gastroesophageal (GE) 
junction adenocarcinoma to three cycles each of pre-and postoperative ECF 
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(epirubicin/ cisplatin/ infusional 5-FU) chemotherapy and surgery or surgery 
alone. peri-operative chemotherapy resulted in significant  improvement  in  5-
year  OS  (36%  versus  23%).  There  was  no  improvement, however, in the 
curative  resection rate,  and  there were no cases of  pCR. Although only 26% of 
patients on this trial had tumors in the GE junction and lower esophagus, the 
results still may apply to esophageal cancer. 
  
                      Finally, data from the French FFCD 9703 trial of 224 patients who 
had gastric or lower esophageal adenocarcinoma recently were presented18.  
Patients were randomized to two or three cycles of preoperative cisplatin/5-FU 
followed by surgery versus surgery alone. Those patients who appeared to 
benefit clinically or radiographically from  preoperative    therapy  or  who  had  
persistent  T3  or  node-positive  disease  at surgery also received an additional 
three or four cycles of chemotherapy. Preoperative chemotherapy  was  
associated  with  a  significant  improvement  in  R0  resection  rate (84% versus 
73%), 5-year disease-free survival (DFS, 34% versus 21%) and 5-year OS  (38% 
versus 24%).  Although  comparisons  between  different  clinical  trials  must be  
made  cautiously,  the  survival  benefit  seen  with  preoperative  cisplatin/5-FU  
on this trial appears to be very similar to that seen with peri-operative ECF in the 
MAGIC trial. Because of the smaller sample size on this trial, however, outcome 
differences in as few as 10 to 15 patients would have changed the trial outcome. 
Also, the trial did not stage patients with endoscopic ultrasound consistently or 
Page |   
 
12
stratify them by pre therapy stage.  In a small-scale trial, even  a slight imbalance  
in pretherapy stage might impact the trial outcome. 
 
                     Overall, recent trials suggest a survival benefit for preoperative 
chemotherapy, although preoperative chemotherapy alone is  associated  with  a  
low  pCR  rate  and inconsistent  improvement  in  the  resection rate. Such a 
survival benefit also was demonstrated in a recent large, individual patient data  
meta-analysis  of  12  randomized trials  involving  preoperative  chemotherapy16.            
This  meta-analysis  revealed  a  5-year  survival  benefit  of  only  4%  with  
preoperative chemotherapy,  with  a  suggestion  of  lesser  benefit  for  
squamous  (4%)  compared with adenocarcinoma histology (7%). 
 
B. ADJUVANT CHEMOTHERAPY  
 
                      Combined-modality therapy in esophageal carcinoma long has 
focused on preoperative strategies. The role of adjuvant therapy has not been 
studied extensively, and the data that are available suggest equivocal results.  
                     Postoperative chemotherapy without preoperative therapy was 
studied in two Japanese randomized trials, where patients who had SCC 
histology were randomized to receive two cycles of chemotherapy with 
cisplatin/vindesine19  or cisplatin/5-FU20 respectively.  Although  the  trial  with  
cisplatin/vindesine  did  not  show  any  survival benefit, an unplanned subset 
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analysis of the trial with cisplatin/5-FU revealed a survival benefit for patients 
who had lymph node involvement (5-year DFS 52% versus 38%).  
                     The  possible   benefit  for  postoperative    therapy   suggested    by  
the  previously mentioned  trials  led  to  a  subsequent  Japanese  trial  that  
randomized  330  patients who  had  SCC  histology  to  surgery  and  either  two  
cycles  of  pre-  or  postoperative cisplatin/5-FU21. Data recently presented in 
abstract form revealed that preoperative chemotherapy was associated with a 
significant improvement in OS compared with postoperative  chemotherapy  
(hazard  ratio  [HR]  0.64,  95%  CI,  0.45  to  0.91), further questioning  the  role  
of  adjuvant  chemotherapy  for  SCC.  A  significant  number  of patients on this 
trial, however, never received postoperative chemotherapy, making the  results  
difficult  to  interpret.  Another  unexpected  finding  is  that  an  unplanned 
subset analysis suggested that the benefit for preoperative therapy over 
postoperative therapy was seen only in patients without lymph node 
involvement, in contrast to the previously mentioned study where a benefit for 
adjuvant chemotherapy over observation was noted in patients who had lymph 
node involvement. 
                     The overall lack of benefit for adjuvant chemotherapy suggested by 
the Japanese trials is consistent with the results of a randomized French trial, 
which also found no survival benefit for 6 to 8 months of adjuvant chemotherapy 
with cisplatin/5-FU22. In fact, there were significantly more complications in the 
chemotherapy group.  
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                     In contrast, a pilot Eastern Cooperative Oncology Group (ECOG) 
trial recently evaluated  four  cycles  of  postoperative  paclitaxel/cisplatin  in  
patients  who  had  node-positive esophageal or GE junction adenocarcinoma23. 
Two-year OS was 60%, which is statistically superior compared with the 
historical control (38%, derived from Intergroup 113 trial). 
                     Trials  involving  adjuvant  radiotherapy  generally  have  reported  
negative  results. A French study randomized 221 patients to surgery alone 
versus surgery followed by radiation and found no survival benefit from 
radiation24. Another randomized study of 130 patients from Hong Kong actually 
demonstrated increased mortality with postoperative radiation (8.7 versus 15.2 
months, in favor of the  no  adjuvant  therapy  group),  with  the  difference  
attributed  to  radiation-related deaths and early metastatic disease25.  
                     Finally, a large prospective Chinese study also failed to detect an OS 
benefit among 495  patients  randomized  to  adjuvant  radiation  or  no  further  
therapy26. A subgroup analysis of  node-positive patients,  however, did show a 
5-year OS benefit favoring the radiation group (35.1% versus 13.1%). 
                     Although   trials of adjuvant   radiotherapy alone have not suggested 
significant benefit, there may be benefit from adjuvant concurrent 
chemoradiotherapy, as suggested the results of the Intergroup trial 116 in gastric 
adenocarcinoma27. This trial revealed a significant improvement in OS and DFS 
for the delivery of postoperative therapy with 5-FU/leucovorin and radiation 
compared with surgery alone as a  relatively modest  20%  of  the  patients  
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treated  had  proximal  gastric  cancers  (with involvement  of  the  GE  junction) 
and primary GE junction cancers, these data may justify the use of postoperative 
therapy in such patients who have not received preoperative therapy. It should 
be noted that the results of this trial have been questioned because of  the  
relatively  inadequate  surgical  resections  that  were  performed; 54% of patients 
had a D0 resection, which is less than a complete dissection of the involved 
lymph nodes. It has been argued that radiation in this setting compensated for 
inadequate surgery and that its benefits may not be seen if a more complete or 
extensive D1 or D2 surgical resection is undertaken. 
 
C. COMBINED NEOADJUVANT CHEMORADIOTHERAPY.  
 
                      Although recent pre- and peri-operative chemotherapy trials have 
indicated a survival benefit, the low rate of pCR and the inconsistent impact on 
rates of operability have led researchers to investigate neoadjuvant 
chemoradiotherapy.  
                      Chemoradiotherapy typically involves regimens of cisplatin or 
mitomycin and continuous infusion 5-FU, with radiotherapy dosages from 30 to 
40 Gy and up to 60 Gy in more recent trials. Such  therapy  results  in  pCR  rates  
of  20%  to  40%, with long-term  survival  of  no  more  than  25%  to  35%28,29.   
Superior survival is achieved consistently, though in patients achieving a pCR to 
chemoradiotherapy (up to 50% to 60% at 5 years)30-34. 
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                      These results are at the expense of significant toxicities, primarily 
hematologic and gastrointestinal (GI), which have been greatest in trials 
employing a higher dose of or twice-daily radiation or in which radiotherapy 
overlapped all cycles of preoperative chemotherapy35. The GI toxicity associated 
with cisplatin/5-FU and radiation includes nausea, mucositis,  and  esophagitis,  
leading  some  investigators  to  mandate placement of enteral feeding tubes 
before treatment initiation.  
                      The seminal phase 3 United States Radiation Therapy Oncology 
Group (RTOG) trial 85-01 demonstrated the superiority of chemoradiotherapy 
over radiation alone36. This nonoperative study compared standard-fractionation 
radiation (64 Gy) with radiation (50 Gy)  plus  concurrent  cisplatin/5-FU.  The  
trial  was  stopped  when  data from 121 patients showed an improved median 
OS in favor of chemoradiotherapy (12.5months versus 8.9 months). Two-year 
survival was also improved in the chemoradiotherapy group (38% versus 10%), 
as was 5-year survival (21% versus 0%)37. Although most patients treated on this 
trial had SCC, long-term survival also was seen in the small number of 
adenocarcinoma patients on the trial, with 13% of patients alive at 5years. 
                     In addition to a survival benefit, disease recurrence was reduced 
significantly by the addition of chemotherapy to radiation. At 1 year, recurrent 
disease was observed in 62% of  the  group    that  received  radiation  versus  
44%  in  the chemoradiotherapy arm. Distant recurrence rates were 38% and 22%, 
respectively. Based on this study, chemoradiotherapy was established as the 
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standard of care in the nonsurgical management of locally advanced esophageal 
SCC. 
                    Building on  these  results,  more  intensive  treatment  strategies  
have  been investigated. In the non-operative RTOG 90-12 chemoradiotherapy 
study, induction chemotherapy with cisplatin/5-FU followed by 
chemoradiotherapy with the same regimen did not appear to afford any 
additional benefit38. The RTOG 94-05 study compared a total radiation dose of 
64.8 Gy versus 50.4 Gy during concurrent cisplatin/5-FU and also failed  to  
demonstrate  superior  results  with  the  more  intense  regimen39. This study 
confirmed 50.4 Gy as the standard radiation dose when given in combined 
therapy with cisplatin/5-FU. Finally, the phase 1/2 RTOG 92-07 trial, which 
attempted to boost radiation with  brachytherapy  following  external  beam  
radiation,  revealed significant toxicity, including a 12% incidence of treatment-
related fistulas40. 
 
                      Five contemporary randomized trials have compared preoperative 
chemoradiotherapy followed by surgery versus surgery alone. The results are 
summarized in the Table 1. 
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Table 1. Results of Preoperative chemoradiotherapy trials in esophageal cancer 
Treatment Histology No. R0 
Resec’n 
rate 
pCR Median 
Survival 
Overall 
Survival 
Local 
Failure 
Ref. 
Pre-op 
CRT 
Surgery 
SqCC (24%) 
+ AdenoCa 
(76%) 
50 
 
50 
45% 
 
45% 
28% 
 
N/
A 
16.9mo 
 
17.6mo 
3y 30% 
 
3y 16% 
19% 
 
42% 
Urba 
et al41 
Pre-op 
CRT 
Surgery 
AdenoCa 58 
 
55 
NS 25% 
 
N/
A 
16mo 
 
11mo 
3y 32% 
 
3y 6% 
NS Wals
h et 
al42 
Pre-op 
CRT 
Surgery 
SqCC 143 
 
139 
81% 
 
69% 
26% 
 
N/
A 
18.6mo 
 
18.6mo 
5y 26% 
 
5y 26% 
NS Bosse
t et 
al43 
Pre-op 
CRT 
Surgery 
SqCC(35%) + 
AdenoCa 
(63%)+ other 
128 
 
128 
80% 
 
59% 
16% 
 
N/
A 
22.2mo 
 
19.3mo 
NS 
 
NS 
15% 
 
26% 
Burm
eister 
et al44 
Pre-op 
CRT 
Surgery 
SqCC(25%) + 
AdenoCa 
(75%) 
30 
 
26 
NS 40% 
 
NA 
4.5yrs 
 
1.8yrs 
5y 39% 
 
5y 16% 
NS 
 
NS 
Teppe
r et 
al45 
 
 
 
D. DEFINITIVE CHEMORADIOTHERAPY IN COMPARISON TO 
NEOADJUVANT CHEMORADIOTHERAPY FOLLOWED BY SURGERY.  
 
                      Two recent randomized trials have compared definitive 
chemoradiotherapy versus chemoradiotherapy followed by surgery. The first 
study was performed by the German Esophageal Cancer Study Group, which 
assigned 172 patients who had SCC to preoperative therapy (three cycles of 
cisplatin/5-FU/leucovorin/etoposide, then cisplatin/etoposide and concurrent 
radiation to 40 Gy) followed by surgery or to the preoperative therapy alone with 
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a higher radiation dose (to at least 65 Gy) in lieu of surgery34. Although local PFS   
was improved with the addition of surgery (HR for chemoradiotherapy-only 
group versus surgery group 2.1, 95% CI, 1.3 to 3.5, P=.003), there was only a non- 
significant trend toward improvement in 3-year OS (31.3% versus 24.4%). 
Treatment-related mortality was also significantly higher in the surgery group 
compared with the chemoradiotherapy-only group (12.8% versus 3.5%). Ten- 
year survival data for this trial recently was presented in abstract form, 
reaffirming the absence of a significant difference between both groups47. 
 
                      The second study is the French FFCD 9102 trial, where 444 eligible 
patients who had mostly SCC histology underwent initial chemoradiotherapy 
with cisplatin/ 5-FU48. Those   who   responded     to initial therapy then were 
randomized either to undergo surgery or to receive an additional three cycles of 
cisplatin/5-FU with radiation, as the authors felt that it would be inappropriate 
to continue chemoradiotherapy in patients not responding to therapy.  Of the 444 
patients, 259 were randomized. The 2-year survival rate was not significantly 
different between both groups (34% in surgery group versus 40% in 
chemoradiotherapy-only group, P=.44). Locoregional recurrence, however, was 
higher in the chemoradiotherapy-only group (43% versus 34%), and there was 
also a higher incidence of stent placement in this group (32% versus 5%). Three-
month mortality was significantly higher in the surgery group (9.3% versus 0.8%). 
Based on these data, the authors concluded that patients who have tumors, 
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especially of SCC histology, that respond to initial chemoradiotherapy did not 
derive any survival benefit from subsequent surgery. Patients who underwent 
surgery did have improved local control of their disease, albeit at the cost of 
increased treatment-related mortality. 
                      An interesting question that arises from this study is whether 
patients who do not respond to initial therapy benefit from subsequent surgery. 
In a recent abstract, the authors discussed the outcome of the 192 of the 451 
registered patients from the previous study who were not randomized to further 
protocol therapy after initial chemotherapy primarily because of a lack of 
response but also because of medical contraindication or  patient  refusal49. Of  
these  nonrandomized  patients,  112  subsequently underwent surgery, with 80 
undergoing R0 resections. The median OS for the patients who underwent 
surgery was significantly superior to the median OS of those who did not (17.3 
versus 6.1 months) and was comparable to the median OS of the patients who 
were randomized. Although there are clear limitations and potential strong 
confounders to such an analysis, these data may suggest that salvage 
esophagectomy can be beneficial for a subset of patients who do not respond to 
initial therapy. 
                      As  a  related  issue,  definitive  chemoradiotherapy  alone  versus 
surgery  alone also recently was compared in a Scandinavian phase 3 trial of 91 
patients with adenocarcinoma and SCC who were randomized to receive either 
cisplatin/5-FU and radiation alone or surgery50. At a median follow-up of 51.8 
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months, there was no survival difference between both groups. Although this 
study may be underpowered to detect small survival differences, the data 
collectively support definitive chemoradiotherapy as an acceptable approach for 
patients who have contraindications to surgery. 
 
CHEMOTHERAPY IN METASTATIC ESOPHAGEAL CARCINOMA 
 
                      A variety of single agents and combination regimens have been 
evaluated in patients with recurrent or metastatic carcinoma of the esophagus. 
These patients often have a high tumor burden and poor performance status 
with little prospect for prolongation of survival. Phase II clinical trials in this 
population have identified drugs with activity that have been integrated into 
combined modality regimens for the treatment of earlier-stage disease. 
 
A. Single-Agent Chemotherapy 
 
                      Studies of single-agent chemotherapy for esophageal cancer are 
summarized here. Response data for many of the older drugs have come from 
broad phase I and II trials conducted in the early 1970s, which included small 
numbers of esophageal cancer patients51-60. Bleomycin, 5-FU, mitomycin, and 
cisplatin have been used most frequently because of their single-agent activity 
and additive or synergistic effects with radiation. Because of the potential for 
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pulmonary toxicity, bleomycin is no longer included in combination regimens, 
having been replaced by 5-FU. Similarly, mitomycin is used less often because of 
its toxicity profile, which includes hemolytic-uremic syndrome and cumulative 
myelosuppression. 
                     Seven trials examined the use of cisplatin for single-agent therapy in 
esophageal cancer patients58,61-66, six of which used dosages ranging from 50 to 
120 mg/m2 every 3 to 4 weeks. The cumulative response rate in patients with 
metastatic or recurrent disease was 21%58,61-66. Administration of the drug as a 
single-bolus dose once every 3 weeks and in a divided dose during 5 days every 
3 weeks appeared to be equally efficacious. Using a more dose-intense schedule 
of cisplatin (120 mg/m2 on day 1 and 15), Miller et al64. observed a 73% response 
rate in 15 patients before surgery. 
                       A randomized phase II trial of cisplatin alone and cisplatin in 
combination with 5-FU in 92 patients with metastatic squamous cell carcinoma of 
the esophagus was reported by the EORTC62. A 19% response rate was observed 
in 45 patients receiving single-agent cisplatin (100 mg/m2 every 3 weeks). The 
response rate in the combination therapy arm was 35%. No studies of single-
agent cisplatin have been performed in patients with adenocarcinoma of the 
esophagus. 
                      Vinorelbine is a semisynthetic vinca alkaloid that has less 
neurotoxicity than vincristine and vinblastine. Phase II trials in metastatic 
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squamous cell cancer of the esophagus report response rates of 20% to 25% using 
weekly or biweekly dosing schedules67,68. 
                      Three trials of single-agent paclitaxel have been reported. One used 
the maximum tolerable dose of 250 mg/m2, derived from initial phase I trials 
using a 24-hour infusion schedule69. The overall response rate was 32% (34% in 
33 patients with adenocarcinoma, and 28% in 18 patients with squamous cell 
carcinoma). All patients had good performance status, were chemotherapy-naive, 
and had distant metastases. The second trial tested a regimen of 140 mg/m2 
infused during 96 hours in patients previously treated using a shorter infusion 
schedule of paclitaxel containing combination chemotherapy77. No responses 
were observed. The third trial evaluated single-agent paclitaxel administered by 
a weekly 1-hour infusion at a dose of 80 mg/m2 in a large multicenter phase II 
setting71. A modest response rate of 15% was observed in 65 patients without 
prior chemotherapy treatment (16% in the 50 patients treated with 
adenocarcinoma and 13% in the 15 patients treated with squamous cell 
carcinoma). 
                    Drugs that have been adequately tested in squamous cell cancer of 
the esophagus and have response rates of less than 5% are trimetrexate, 
etoposide, ifosamide, and carboplatin. Therefore, substitution of single-agent 
carboplatin for cisplatin is not recommended when treating patients with either 
adenocarcinomas or squamous cell carcinomas of the esophagus 
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B. Combined-Agent Chemotherapy 
 
                     Older trials (before the mid-1990s) and those in Europe were almost 
exclusively limited to patients with squamous cell carcinoma. Because 
esophageal cancer is a relatively uncommon malignancy, many studies include a 
heterogeneous population of treatment-naive patients with locally advanced 
intrathoracic disease as well as patients with recurrent or metastatic disease. Not 
only is there variation in the patient population, but more recent trials usually 
limit eligibility to patients with no prior chemotherapy and performance status 
of 0 or 1. Thus, in the absence of comparative trials, newer regimens may appear 
more effective. 
                     The results for platinum-based combination chemotherapy regimens 
are detailed in Table 272,73,62,74,75-93. Most series consist of small numbers of 
patients; therefore, the 95% confidence intervals are large and nearly all 
responses are partial. On average, duration of response ranges from 3 to 6 
months. No specific regimen has yet emerged as more efficacious and less toxic 
than cisplatin and 5-FU. 
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Table 2. Selected Combination Chemotherapy Regimens for Recurrent and 
Metastatic Carcinoma of the Esophagus 
Regimen 
Evaluable 
Patients (n) Histologic Type 
% CR + 
PR References 
Cisplatin + 
bleomycin 
17 S 17 72 
Cisplatin + 
bleomycin + 
vindesine 
51 S 31 76 
Cisplatin + 
bleomycin + 
Methotrexate 
40 S 30 77,78 
Cisplatin + 
mitoguazone + 
vindesine 
20 S 40 79 
Cisplatin + 
mitoguazone + 
vinblastine 
36 S 11 80 
Cisplatin + 5-FU 82 S 35 62 
Oxaliplatin + 5-
FU 
34 A/S 40 88 
Carboplatin + 
vinblastine 
16 S 0 81 
Cisplatin + 
vinorelbine 
71 S 34 74 
13-cis-retinoic 
acid + 
interferon-
2alpha 
15 S/A 0 84 
5-FU + 
interferon 
57 S/A 26 82,95 
Cisplatin + 5-FU 
+ interferon 
66 S/A 53 (62% S, 
32% A) 
83,96 
Cisplatin + 
etoposide 
  
65 S 48 85 
27 A 48 92 
Cisplatin + 
etoposide + 5-
FU + leucovorin 
69 S 34 97 
CR, complete response; PR, partial response; S, squamous cell carcinoma; 5-FU, 5-
fluorouracil; A, adenocarcinoma of esophagus, gastroesophageal junction, cardia; G, gastric 
cancer 
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Regimen 
Evaluable 
Patients (n) 
Histologic 
Type % CR + PR References 
Paclitaxel (24 h) + 
cisplatin every 3 wk 
32 S/A 44 (25% S, 
46% A) 
100 
Paclitaxel (3 h) + 
cisplatin every 2 wk 
51 S/A 43 98 
Paclitaxel (3 h) + 
cisplatin every wk 
Ã— 6 
24 A 50 99 
Paclitaxel (3 h) + 
cisplatin + 5-FU 
every 4 wk 
60 S/A 48 (56% S, 
46% A) 
101 
Paclitaxel (1 h) + 
carboplatin every 
week 
37 S/A 54% 93 
Irinotecan + 
cisplatin every wk 
Ã— 4, every 6 wk 
35 S/A 57 (66% S, 
52% A) 
102 
Irinotecan + 
cisplatin every wk 
Ã— 4, every 6 wk 
25 A 51 103 
Docetaxel + 
irinotecan every wk 
Ã— 3, every 4 wk 
24 S/A 13 105 
Docetaxel + 
irinotecan every 3 
wk 
46 A 26 104 
Mitomycin + 
cisplatin + 5-FU 
Vs. 
Epirubicin + 
cisplatin + 5-FU 
285 
Vs. 
289 
A/G 
Vs. 
A/G 
46% A,  
38% G 
Vs. 
44% A, 
 36% G 
94 
  
CR, complete response; PR, partial response; S, squamous cell carcinoma; 5-FU, 5-
fluorouracil; A, adenocarcinoma of esophagus, gastroesophageal junction, cardia; 
G, gastric cancer 
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Dose intensified Cisplatin based chemotherapy: 
 
                      Cisplatin is one of the most active chemotherapeutic agents in 
epithelial cancers, especially esophageal cancers. The analysis of dose-intensity 
(dose delivered per unit time) is considered the most appropriate method of 
analyzing dose-response relationships106. 
 
                       To  standardize  terminology,  dose-intensity  is  usually  expressed 
as milligrams per square meter per week, regardless  of  the actual  schedule  of 
administration. Conventional chemotherapy regimens in esophageal cancer 
using Cisplatin achieve a dose intensity ranging from 15mg/m2/week to about 
35mg/m2/week. 
 
Rationale of the Proposed Study:  
 
                        This pilot study builds on the data that Cisplatin based 
chemotherapy is the standard of chemotherapeutic management of esophageal 
carcinomas, both in the adjuvant and metastatic scenarios. By the proposed 
dosing of induction chemotherapy using Cisplatin and 5-Fluorouracil, the 
following objectives are being tested; 
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1. A Greater dose intensity is achieved by increasing the dose to 200mg/m2 
delivered over 5weeks, which in the conventional treatment is delivered over 6-
8weeks. 
Dose intensity achieved is equivalent to 40mg/m2/week. In common 
conventional chemotherapy regimens, the dose intensity achieved is in the range 
of 15-35 mg/m2/week. 
2. A greater dose intensity will improve the response rates to treatment 
3. A higher dose intensity also decreases the chances of accelerated repopulation 
by resistant and less responsive clones of malignant cells, which will reduce 
recurrence rates and thus, has the ability to improve survival. 
4. An improved response rate will help achieve an earlier and possibly more 
sustained dysphagia relief to the patient, and tumor down staging to the treating 
physician. 
5. By using cheaper and readily available conventional chemotherapeutic drugs 
and optimizing the dose intensity there after, an affordable and new standard of 
care in chemotherapeutic management of esophageal cancer is envisaged. 
 
Possible drawbacks of this treatment regimen 
 
1. Inpatient treatment 
2. Longer hospital stay 
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3. Higher incidence of toxicity of therapy, especially Cisplatin related toxicity viz. 
Emesis, Nephrotoxicity, Neurotoxicity and Ototoxicity. This can be circumvented 
by fractionating the dose into 10 equal doses given over 10days and improving 
the hydration and supportive care along with careful and close monitoring of the 
patient. 
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AIM OF THE STUDY 
 
This trial is designed to determine if the treatment arm under consideration is  
promising enough to be pursued in a phase II study. 
 
• To determine the feasibility of treatment delivery, patient tolerance, and acute 
toxicities 
• To describe the response (including dysphagia relief) on completion of the test 
chemotherapy schedule. 
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SUBJECTS AND METHODS 
PATIENT SELECTION 
(Note: As per NCI (National Cancer Institute), USA guidelines, exceptions to 
eligibility are not permitted)   
 
1 Conditions for Patient Eligibility  
 
1.1 Pathologically (histologic or cytologic) proven diagnosis of primary 
squamous cell or adenocarcinoma of the esophagus or esophageal-gastric 
junction within 12 weeks prior to registration 
1.1.1  Patients with celiac, perigastric, mediastinal or supraclavicular             
          adenopathy are eligible.    
1.1.2 Patients with cervical esophageal carcinoma are eligible 
1.1.3 Patients with non-regional adenopathy and distant metastasis are   
         eligible 
 
1.2 Stage T1N1M0; T2-4, Any N, M0; Any T, Any N, M1a, M1b based upon the 
following minimum diagnostic work-up:  
1.2.1  History/physical examination within 6 weeks prior to registration  
1.2.2  Chest/Whole Abdominal CT within 6 weeks prior to registration   
1.2.3  ECG within 6 weeks of study entry  
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1.2.4  Endoscopy with biopsy or cytology by  fine needle aspiration (FNA) 
(must be able to document histologic subtype) within 12 weeks of study 
entry. Patients with T3-4 proximal thoracic esophageal tumors (15-25 cm) 
must undergo bronchoscopy to check for fistula.  
(NOTE: Any images from endoscopic procedures up to the time of progression 
must be kept in the patient’s confidential study file.)  
1.3  Zubrod/ECOG performance status 0-2  
1.4  Age ≥ 18  
1.5  CBC/differential obtained within 2 weeks prior to registration on study, 
with adequate bone marrow function defined as follows:  
1.5.1  Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3  
1.5.2  Platelets ≥ 100,000 cells/mm3 
1.5.3  Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other 
intervention to achieve Hgb ≥ 8.0 g/dl is acceptable.)  
1.6  Additional laboratory studies obtained within 2 weeks prior to registration 
on study  
1.6.1   Creatinine ≤ 1.5 mg/dl  
1.6.2   Bilirubin ≤ 1.5 x upper limit of normal  
1.6.3   AST ≤ 3 x upper limit of normal  
1.6.4  Serum pregnancy test for women of childbearing potential  
1.7 Patient’s total intake (oral/enteral) must be ≥ 1500 kCal/day  
1.8  Patient must provide study-specific informed consent prior to study entry  
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1.9  Women of childbearing potential and male participants must practice 
adequate contraception  
 
 2 Conditions for Patient Ineligibility  
 
2.1 Prior invasive malignancy (except non-melanomatous skin cancer) unless 
disease free for a minimum of 2 years (For example, carcinoma in situ of the 
breast, oral cavity, or cervix are all permissible).   
2.2 Prior systemic chemotherapy for esophageal cancer; note that prior 
chemotherapy for a different cancer is allowable. See Section 2.1.   
2.3 Prior radiation therapy that would result in overlap of planned radiation 
therapy fields.   
2.4 Prior platinum-based therapy.   
2.5 Prior allergic reaction to the study drugs involved in this protocol.  
2.6  Severe, active comorbidity, defined as follows:  
2.6.1 Unstable angina and/or congestive heart failure requiring  
         hospitalization within the last 3 months  
2.6.2  Transmural myocardial infarction within the last 6 months  
2.6.3  Acute bacterial or fungal infection requiring intravenous antibiotics  
          at the time of registration  
2.6.4 Chronic obstructive pulmonary disease exacerbation or other  
         respiratory illness requiring hospitalization or precluding study  
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         therapy at the time of registration   
2.6.5  Acquired immune deficiency syndrome (AIDS) based upon current  
         CDC definition; note, however, that HIV testing is not required for   
         entry into this protocol. The need to exclude patients with AIDS from  
         this protocol is necessary because the treatments involved in this  
         protocol may be significantly immunosuppressive.  Protocol-specific  
         requirements may also exclude immunocompromised patients.  
2.7 Pregnancy or women of childbearing potential  and men who are sexually 
active and not willing/able to use medically acceptable forms of  contraception; 
this exclusion is necessary because the treatment involved in this study may be 
significantly teratogenic.   
2.8 Women who are nursing. 
 
PRETREATMENT EVALUATIONS 
 
Required Evaluations  
1. Complete history and exam including weight with an assessment of the 
patient's performance status;   
2. All patients must be evaluated by a Medical Oncologist prior to study entry.    
3. Laboratory Studies  (within 2 weeks prior to treatment)  
• CBC 
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• Serum creatinine, electrolytes, SGOT, AST, LDH, alkaline phosphatase, 
total bilirubin, total protein, albumin, uric acid, inorganic phosphorous, 
calcium, BUN, magnesium).   
• Calculated creatinine clearance (optional)  
      A venous access(an IV line, a long line, subclavian catheter, or implantable 
device) will be established in all patients.  
4. Imaging Studies(within 4 weeks prior to randomization)  
• CT Scan of the Chest and Abdomen  (MRIs are acceptable)  
• Upper GI endoscopy  (Endoscopic ultrasonography and double contrast 
upper GI radiographs are highly recommended but not required.)  
• Chest X-ray  
• Data on T stage, N stage will be collected. 
• Whenever possible, EUS/FNA of the nodes is highly desirable to improve 
accuracy.   
5. Bronchoscopy is required if the lesion is < 30 cm from the incisors to exclude 
TE fistula or invasion.  
6. Biopsy of supraclavicular node if clinically or radiographically enlarged;  
7. Lymph node biopsy is not mandatory. Nodes < 1 cm need not be biopsied. For 
nodes 1-2 cm, a biopsy should definitely be considered.  
8. ECG; bone scan (if alkaline phosphatase is elevated ≥ 1 .5 x normal);  
9. Nutritional Assessment  
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Patients should ingest either more than 1.5 x their Basal Energy Expenditure 
(BEE) as measured by the Harris-Benedict equation or more than 1,000 calories 
per square meter of body surface area  (1700 calories for the average 1.7 meter 
individual). If the patient is not able to ingest this amount by mouth, a 
gastrostomy or jejunostomy tube to accomplish this is required. Intravenous 
hyperalimentation is discouraged. The nutritional supplements should amount 
to a minimum  1.75 x the BEE or 1200 calories per square of body surface area but 
no more than 2.25 x the BEE or 1600 calories per meter square of body surface 
area unless the patient can be shown to be hypometabolic.  
 
Patients should be instructed about food intake during treatment.  Instructions 
should include recommending the avoidance of irritants (including alcohol, 
citrus/acidic foods, sharp foods, or foods with extreme temperatures).  
Documentation of any nutritional intervention, including oral high- protein 
nutritional supplements, feeding tubes, and parenteral or enteral nutrition is 
required.  
10. Harris-Benedict Equation to Measure BEE   
Men  
 66.4730 + (13.7516 x wt in kg) + (5.0033 x ht in cm) - (6.75 x age)  
Women  
 655.0955 + (9.5634 x wt in kg) + (1.8496 x ht in cm) - (4.6756 x age)  
  
Page |   
 
39
Daily Caloric Requirement = BEE x 1.75  
 Daily Protein Requirement = Caloric Requirement x 6.25  
                                                              150  
Optional Evaluation  
  2.1 Bilateral audiogram (encouraged in patients with clinical hearing loss) 
 
TREATMENT: CHEMOTHERAPY 
 
Protocol treatment must begin within 10 business days after registration.   
Induction Chemotherapy  
1. Schedule 
• Inpatient administration of chemotherapy is mandatory. Patients will 
need an intravenous line or a double lumen central line placed for 
chemotherapy administration.  
• Chemotherapy schedule will be as follows:  
  
DRUGS Daily DOSE Schedule On DAYS 
Cisplatin 20mg/m2 i.v. in 1hour 1-10 
5-Fluorouracil 250mg/m2 8hour i.v. infusion 1-10 
 
• Subsequent courses of off-protocol chemotherapy may be decreased by 
20% based on toxicity experienced during the test course; however, the 
doses of chemotherapy drugs will not be increased.  
• Adequate hydration, electrolyte supplementation, and anti-emetic 
support will be provided when administering cisplatin. Patients will 
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receive at  least 1.0 liter of 1/2 NS with magnesium and potassium 
supplements intravenously on all cisplatin days. All patients will be 
encouraged to drink at least 2L of fluid daily.   
  The subsequent course of off-protocol treatment will be initiated not earlier than 
day 36 provided the patient has recovered from all toxicities (grade < 1) except 
alopecia and provided that peripheral counts  (absolute granulocyte count 
>1,500/µL and platelet count >100,000/µL) are adequate.   
 
2. Further off-protocol therapeutic decision making  
  The following decision guidelines will be used for recommending the next step, 
after patients have received course of chemotherapy on protocol:  
   
a. In case of Localized Disease at the time of registration 
• Local progression after the first cycle of chemotherapy- Proceed to 
chemoradiotherapy  
• Any response to the test course of chemotherapy- Assessment of 
resectability by the Surgical Gastroenterologist 
a. If resectable-Proceed  with surgery 
b. If still unresectable- proceed with Cisplatin based conventional 
institutional chemotherapy  
• Stable disease-Proceed to chemoradiotherapy. 
• Development of distant metastases anytime  Salvage therapy off protocol 
b. In case of Metastatic Disease at the time of registration 
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• Local progression or development of new sites of metastases - Salvage 
therapy which may include chemotherapy and/or radiotherapy and/or 
surgery as required. 
• Any response- Proceed with Cisplatin based conventional institutional 
chemotherapy until progressive disease or 6 cycles whichever is earlier. 
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LOCALLY ADVANCED DISEASE
INDUCTION CHEMOTHERAPY
(Test Schedule of chemotherapy)
Any Response SD / LOCO-REGIONAL PD Development of 
Metastatic Disease
Conventional Chemotherapy
(Institutional regimen)
2 more cycles and
assess for resection
CHEMORADIOTHERAPY
And assess response
SALVAGE CHEMOTHERAPY
and/or RADIOTHERAPY
Response Assessment
SD-Stable Disease, PD-Progressive Disease
METASTATIC DISEASE
INDUCTION CHEMOTHERAPY
(Test Schedule of chemotherapy)
Any Response,or
SD for >24wks
PD
Conventional Chemotherapy
(Institutional regimen)
SALVAGE CHEMOTHERAPY
and/or RADIOTHERAPY
Response Assessment
SD-Stable Disease, PD-Progressive Disease
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3. Dose Modifications for Chemotherapy treatment thereafter    
 
                     Reduction of chemotherapy dose will be based on the degree of 
hematologic and non-hematologic toxicities. The goal is not to induce grade 3 
nonhematologic toxicity or grade 4 hematologic toxicity.  
                     If the granulocyte level drops below 1000, counts should be 
performed every other day until the level rises above 1000.  
Dose modification cisplatin based on hematologic toxicities 
  
Granulocyte Nadir     Platelet Nadir Dose Modification  
 
>1,000 AND >75,000 No Change  
> 500 but <1,000 AND/OR >50,000 but <75,000 No Change  
<500 for more than >5  
days 
AND/OR <50,000 decrease 20% 
Infection or bleeding  
related to  
myelosuppression 
  decrease 20% 
 
                     The following dose modifications for 5-FU and cisplatin based on 
non-hematologic toxicities will be applicable to all subsequent courses. 
 
Toxicity Grade Dose Modification  
0-2 No Change  
3* or 4 Decrease 20%  
  
*Does not apply to alopecia or grade 3 nausea and vomiting   
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Dose modification for cisplatin based upon renal insufficiency will be as 
follows:  
  
 
 
 
 
*In a well-hydrated state (2 readings necessary when abnormal)  
Anaphylaxis (Cisplatin)  
                   Severe allergic reactions to cisplatin are not uncommon.  Patients who 
exhibit anaphylactic-type allergic reactions should not receive further cisplatin.  
Nonhematologic Toxicity  
                   The following toxicities are anticipated: nausea, vomiting, diarrhea, 
mucositis, phlebitis, fatigue, anorexia, myelosuppression, thrombocytopenia, 
renal dysfunction, ototoxicity, peripheral neuropathy, and dry skin.  
                   This study will utilize the CTC version 3.0 for toxicity and Adverse 
Event reporting. A copy of the CTC version can be downloaded from the CTEP 
home page (http://ctep.info.nih.gov). The dose levels of cisplatin are outlined in 
the following table: 
 Dose levels cisplatin  mg/m2 
Starting 20 
20% decrease 16 
 
Dose Modification of Cisplatin  
Dose reductions for neurotoxicity, mucositis, fatigue  (grade 4 only), oto-, and 
renal toxicity are outlined in the following table: 
  
Serum Creatinine*(mg/dL) Daily Dose  
< 1.4 No change  
> 1.4 but < 2.0 Decrease 50%  
> 2.0 Discontinue 
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Neurotoxicity/  
Fatigue*/  
Mucositis 
Ototox.  Creatinine  
Clearance  
 
 Creatinine Dose Level,  
Cisplatin  
  ≥ 60 ml/min Or  ≤ 1.5 Starting 
dose- 
20 mg/m2 
  50≤ 
clearance<  
60 
Or 1.5 < creatinine 
<2 
Decrease 20%  
to 16 mg/m2 
    < 50 ml/min   Or ≥ 2 Hold 
cisplatin  
Initial Grade 3-
4    
    Decrease 20%  
to 16 mg/m2 
 Severe Any  Any Hold 
Cisplatin 
  
*Modification for grade 4 fatigue only and of > 5 days duration.  
                    Dose reductions for cisplatin will be made on the basis of the serum 
creatinine on the day of treatment, or on the development of grade 3-4 
neurologic or ototoxicity, fatigue (grade 4 only and of ≥ 5 days duration), 
mucositis, diarrhea  (grade 4 only), or nausea/vomiting/dehydration (grade 4 
only). A creatinine clearance (optional) may be obtained to evaluate a rise in 
serum creatinine and may also be used to adjust the cisplatin dose.  However, a 
creatinine clearance is not mandatory. If the serum creatinine on the day of 
treatment is > 1.5 mg/dl but < 2.0 mg/dl, and the serum creatinine is used to 
adjust the dose, the patient should be euvolemic and the value must be 
confirmed by a second serum creatinine.  Modification for grade 4 diarrhea or 
grade 4 nausea/vomiting/ dehydration (hospitalization required) will be made 
for cisplatin only; no modification of paclitaxel will be made for these toxicities.  
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                     With the 1st cycle of chemotherapy, reduction of cisplatin will not be 
based on nausea, vomiting, diarrhea, or dehydration but on stated level of 
neurotoxicity or mucositis (grade 3-4) or fatigue (grade 4 only).  
                     With the subsequent cycle of chemotherapy, dose modifications will 
be based on other grade 3-4 toxicities, including nausea, vomiting, dehydration, 
or diarrhea.  
 Toxicity Grade  
(Nausea/Vomiting/Diarrhea/Dehydration) 
Cisplatin Dose  
Modification  
0-3 No Change  
Initial Grade 4 (Hospitalization) Decrease 20%   
 
 If more than one grade 3-4 nonhematologic toxicity attributable to cisplatin 
occurs during the 1st cycle, then a single dose modification of cisplatin for the 
greatest toxicity observed will be made for the 2nd  cycle 
 
Dose Modification During FU Chemotherapy  
                     Potential toxicities of chemoradiotherapy include nausea, loss of 
appetite, vomiting, malaise, mucositis, hand-foot syndrome, and rarely 
myelosuppression and neuropathy. Major toxicities include mucositis, hand-foot 
syndrome, and rarely diarrhea. Patients will be observed weekly. 
                    5-FU doses will be modified as follows based on the level of toxic 
effects observed during chemotherapy:  
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Toxicity 
Grade 
Dose Modification  
0-2 No change  
3 or 4* Hold 5-FU for 5 days and resume, provided the toxicity has 
substantially resolved or grade <1. 
   *Does not apply to alopecia or grade 3 nausea and vomiting 
 
3. Agents 
 
A. Cisplatin (CDPP)  
Formulation  
Cisplatin is available as a 1 mg/ml solution in 10, 50 and 100 mg vials.  
Pharmacology  
The dominant mode of action of cisplatin appears to involve the formation of a 
bifunctional adduct resulting in DNA crosslinks.  How this kills the cell remains 
unclear.  There are data to indicate that its mode and sites of action are different 
from those of nitrogen mustard and the standard alkylating agents. Plasma levels 
of cisplatin decay in a biphasic mode with an initial half-life of 18 to 37 minutes, 
and a secondary phase ranging from 44 to 190 hours.  This prolonged phase is 
due to protein binding which exceeds 90%.  Urinary excretion is incomplete with 
only 27 to 45% excreted in the first five days.  The initial fractions are largely 
unchanged drugs.  
Supplier  
Cisplatin is available commercially and supplied by the Government drug store   
Storage  
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The intact vials should be stored at room temperature.  Once reconstituted, the 
solution should be kept at room temperature to avoid precipitation.  Due to a 
lack of preservatives, the solution should be used within eight hours of 
reconstitution.  The solution may be further diluted in a chloride containing 
vehicle such as D5NS, NS, or D5-1/2NS (ppt. occurs in D5W).  Cisplatin has been 
shown to react with aluminum needles, producing a black precipitate within 30 
minutes.  Cisplatin should be given immediately after preparation as a slow 
intravenous infusion.  
Side Effects and Toxicities  
Includes anorexia, nausea, vomiting, renal toxicity  (with an elevation of BUN, 
creatinine, and impairment of endogenous creatinine clearance, as well as renal 
tubular damage which appears to be transient), ototoxicity  (with hearing loss 
which initially is in the high-frequency range, as well as tinnitus), hyperuricemia, 
seizures, rash, ocular toxicities, rare cardiac abnormalities, or possible acute 
myeloid leukemia.  Much more severe and prolonged toxicity has been observed 
in patients with abnormal or obstructed urinary excretory tracts.  
Myelosuppression, often with delayed erythrosuppresion, is expected.  In the 
high-dose treatment regimen with osmotic diuresis, the nadir of white cells and 
platelets occurred regularly at about two weeks with recovery generally at about 
three weeks after the initiation of therapy.  Rare complications are loss of taste, 
allergic reactions, and loss of muscle or nerve function. 
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B. Fluorouracil (5-FU)  
Formulation  
 5-FU is available in 5-ml ampules, as a colorless to faint yellow aqueous solution 
containing 250 mg 5-FU, with pH adjusted to approximately 9.0 with sodium 
hydroxide.  Administration of 5-FU should be only by the intravenous route 
taking care to avoid extravasation.  
Pharmacology  
 5-FU is a marketed drug available in 500 mg vials.  It is fluorinated pyrimidine 
belonging to the category of antimetabolites.  5-FU resembles the natural uracil 
molecule in structure, except that a hydrogen atom has been replaced by a 
fluorine atom in the 5 position.  
                     There is evidence that the metabolism of fluorouracil in the anabolic 
pathway blocks the methylation reaction of deoxyuridylic acid to the thymidylic 
acid.  In this fashion 5-FU interferes with the synthesis of DNA and to a lesser 
extent inhibits the formation of ribonucleic division and growth; the effect of 
fluorouracil may be to create a thymidine deficiency which provides unbalanced 
growth and death of the cell.  
Supplier  
 5-FU is available commercially and supplied by the Government drug store.  
Storage  
Although 5-FU solution may discolor slightly during storage, the potency and 
safety are not adversely affected.  Store at room temperature  (49°-86°F).  Protect 
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from light.  If a precipitate occurs due to exposure to low temperatures, 
resolubilize by heating to l40°F with vigorous shaking; allow to cool to body 
temperature before using.  
Side Effects and Toxicities  
The spectrum of toxicity includes stomatitis and esophagopharyngitis (which 
may lead to sloughing and ulceration), diarrhea with cramping and/or bleeding, 
anorexia, nausea and emesis are commonly seen during therapy.  Leukopenia 
usually follows every course of adequate therapy with fluorouracil. The lowest 
white blood cell counts are commonly observed between the 9th and l4th days 
after the first dose, although uncommonly, the maximal depression may be 
delayed for as long as 20 days.   
                       By the 30th day the count has usually returned to the normal range. 
Alopecia and dermatitis may be seen. The dermatitis most often seen is a pruritic 
maculopapular rash usually appearing on the extremities and less frequently on 
the trunk.  Other side effects include myocardial ischemia, angina, lethargy, 
malaise, headache, allergic reactions, disorientation, confusion, euphoria, 
dizziness, uncoordination, visual changes, photosensitivity (eyes and skin), nail 
changes including loss of nails, skin thickening, cracking, dryness or sloughing, 
vein pigmentation, biliary sclerosis, or acaculous cholecystitis.  
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PATIENT ASSESSMENTS 
1. Study Parameters   
Parameter Prior to 
Randomization 
(≤ 28 days) 
 
During 
the 
chemo 
cycle 
After 
the 
chemo 
Week 6 from 
D-1 of 
chemotherapy 
Initiation 
History & Physical 
Exam’n 
+ + + + 
CBC, diff, platelets +(e) +(a) + + 
Blood & Serum 
Chem (g) 
+(e) +(a) + + 
CXR-PA +(e)   + 
Bronchoscopy (f) +   + 
Barium contrast X-
rays 
+(c)   + 
Chest & Abdominal 
CT 
(MRIs acceptable) 
+   + 
ECG +    
Endoscopy & USG 
(Endo-USG not 
mandatory) 
+   + 
Bone Scan  +(d)   +(d) 
PFTs +(c)    
Biopsy +   As needed 
Toxicity   + + 
  
a. must be done thrice in a week during chemotherapy  
b. if clinically indicated  
c. optional (but highly desirable)  
d.  if serum alkaline phosphatase elevated ≥ 1.5 times normal  
e.  within 2 weeks prior to randomization  
f.  if tumor is < 30 cm from the incisors.  
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g. serum creatinine, electrolytes, SGOT, AST, LDH, Alk phos, total bilirubin, total 
protein, albumin, uric acid, phos, calcium, BUN, mg  
 
2. Criteria for Response   
                     These tumors are not measurable and thus, response is not the 
primary endpoint of this study. 
                     The rate of negative endoscopy or regression in tumor bulk at Day 36 
would be the equivalent of a complete response or partial response, respectively.   
3. Criteria for Progression of Disease  
• While it is recognized that it is not always possible to obtain pathologic 
proof of progressive disease, biopsy or autopsy material confirming 
recurrent cancer is highly desirable and every reasonable attempt to 
obtain such is encouraged.   
• In the absence of histologic or cytologic proof of recurrence, clinical 
evidence (including new masses on CT scan, new lesions on bone scan, 
ascites not explained by other causes, or enlarging mass by endoscopic 
U/S), although highly suspicious of recurrent disease will not result in 
change in the patient's management. These findings should lead to a 
search for a mass that could be biopsied.   
• Patients who develop progression of disease at the primary site while 
receiving test chemotherapy schedule or develop metastatic disease will 
be considered treatment failures. They may be treated with any form of 
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palliative therapy at the discretion of the treating medical oncologist 
based on institute policy. 
• Patients who develop local recurrence only may be offered surgery; they 
will be considered treatment failures.  Those who develop metastases may 
be offered chemotherapy. They will be considered treatment failures. The 
regimen chosen may include a variety of phase II agents under study or 
conventional chemotherapy.   
• The dates and sites of all failure patterns must be reported.  
 
4. Criteria for Removal From Study Analysis  
                   Efforts shall be made to account for all patients entered into the study 
during the evaluation of results. However, in detailed evaluation, the following 
patient categories will be considered.  
• Early Deaths: Those patients who died within six weeks of beginning 
therapy as a result of an event not related to esophageal cancer or to the 
study drugs.  
• Lost to Follow-up: Those patients in whom there is inadequate 
information to judge tumor response because of loss of contact in which 
repeated attempts to obtain information are unsuccessful.   
• Major Protocol Violations: Patients who receive further therapy or deviate 
from the treatment program by either adding a chemotherapeutic agent or 
by substantially modifying the dosage and schedule of the study drugs. 
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RESULTS 
STUDY POPULATION AND COMPLIANCE TO TREATMENT 
                       Between May 2009 and April 2010, 30 patients met the eligibility 
criteria of the protocol and were recruited. Three patients were excluded from 
the study because they opted out of the protocol therapy early on (one patient), 
did not receive protocol therapy (one patient), or had delinquent data (one 
patient). The remaining 27 patients are considered in the feasibility, toxicity and 
response analysis.  Table 3 lists pretreatment patient and tumor characteristics. 
 
                        The median age was 56years (Range 25years to 67years). Men 
comprised 78 % of patients. 78% patients were current or former smokers, 55% 
were alcohol abusers and about 10% of them were tobacco chewers. 89% of 
patients consumed non-vegetarian food also in their diet. The performance status 
by ECOG was 1 in 74% and 2 in 26% of patients. By histological subtype, as 
determined by the pathology department of our institution at the time of 
registration, 89% were Squamous cell carcinoma and 11% were adenocarcinoma. 
2 patients had a history of reflux disease and were diagnosed with 
adenocarcinomas of the lower third of esophagus. The grade of disease was 
Grade- III in 45% of patients, Grade-II in 33% and Grade-I in 22% of patients. The 
sites of disease, as determined by endoscopy and imaging investigations at the 
time of registration were upper one-third of thoracic esophagus in 15% of 
patients, middle one third in 55% of patients and lower third of thoracic 
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esophagus in 30% of patients. None of the patients registered had a primary 
disease of the cervical esophagus or esophago-gastric junction. 37% patients had 
metastatic disease at presentation. Common sites of metastasis were non-regional 
lymph nodes and lung. 15% and 22% patients had tracheo-esophageal fistula and 
aortic infiltration, respectively. 
                       Dysphagia was the most common and troubling symptom at 
presentation. Nausea, Vomiting and pain were the other common symptoms 
complained by the patients. Nasogastric tube feeding was required prior to 
treatment in 48% of patients. 
                       The chemotherapy regimen was according to protocol specification 
in all patients (100%). The duration of protocol-administered treatment was 10 
days in all the 27 patients (100%). All the patients received both Cisplatin and 5-
Fluorouracil as per protocol specification without interruption or deviations.  A 
delay to start subsequent off-protocol conventional therapy was observed in 27% 
of patients. This was significant in 4 patients who had a delay of 7-14 days, but 
not unusual. It was related to the toxicity of protocol-administered therapy. 
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Table 3. Distribution of Patient and Tumor Characteristics 
Variable No. of  
Patients 
Percentage %* 
SEX 
       Male 21 78 
       Female 6 22 
AGE (years) 
       Median 56 years 
25- 67 years        Range 
ECOG Scale 
1 20 74 
2 7 26 
HABITS 
       Smoking   21 78 
       Alcohol abuse 15 56 
Tobacco Chewing 3 11 
HISTORY OF 
 REFLUX DISEASE  
2 7 
HISTORY OF 
CAUSTIC INJURY 
1 4 
DIET 
       Mixed 24 89 
       Vegetarian 3 11 
* Percentages have been rounded, not all percentages add up to 100%        
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Variable No. of  
Patients 
%* 
COMMON SYMPTOMS  
       Dysphagia 27 100 
       Nausea/Vomiting 12 44 
       Pain 8 30 
       Abdominal Pain 2 7 
       Loss of Appetite & Weight 2 7 
       Neck Swelling 1 4 
FEEDING TUBE PRIOR TO TREATMENT 
        YES 13 48 
         NO 14 52 
SITE 
Upper third thoracic 4 15 
Middle third Thoracic 15 55 
Lower third Thoracic 8 30 
PATHOLOGICAL SUBTYPE 
Squamous Cell Carcinoma 24 89 
Adenocarcinoma 3 11 
GRADE (Squamous Cell Carcinoma) 
       Grade- I 6 22 
       Grade- II 9 33 
       Grade-III 12 45 
AJCC Stage Grouping (2002) 
       Stage IIA 5 18 
       Stage IIB 2 8 
       Stage III 10 37 
       Stage IVA 4 15 
       Stage IVB 6 22 
* Percentages have been rounded, not all percentages add up to 100%        
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ACUTE TOXICITY 
 
                            Acute toxicities were manageable and did not cause life 
threatening or crippling consequences. There were no treatment related deaths. 1 
patient experienced acute grade-4 toxicity and 4 patients had acute grade-3. The 
acute grade 4 toxicity observed was hematological toxicity. Grade 3 toxicities 
observed were hematological toxicity, nausea/vomiting and febrile neutropenia. 
Table 4 lists the type and frequency of side-effects.    
 
                           A delay in starting subsequent therapy was observed in 10 
patients. This was 7-14 days in 4 patients and was due to febrile neutropenia. 
Other patients (6) had a delays ranging from 1-5 days and these were considered 
acceptable. Creatinine Clearance was measured pre-treatment and week 5 post-
treatment (Table 5). There was a ≤10ml/min drop in 18patients. In 9 patients, the 
drop in creatinine clearance was 11-20ml/min. This was probably due to the 
high dose intensity of Cisplatin. However, only 3 of the latter group of patients 
had elevation of Serum creatinine ≥ 1.5mg/dl, which normalized over ≤6 days 
and thus, did not mandate dose modifications in subsequent therapy. Of the 14 
patients who did not have any feeding tube placement prior to the start of 
treatment, 4 patients received feeding tube placement during or after treatment. 
At the time of response assessment, 23 patient had felt subjective improvement 
and feeding tube was removed in 13patients. 
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Table 4 - Type and Frequency of Acute Side effects Observed in 27 patients 
 No. of Patients 
Toxicity Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
Hemoglobin 9 - 4 - - 
Leucocytes 17 6 3 1 - 
Neutrophils 11 6 3 1 - 
Platelets 16 2 3 - - 
Infection, Febrile  
Neutropenia 
- - 4 - - 
Mucositis 10 17 - - - 
Dehydration 7 5 - - - 
Nausea/Vomiting - 23 4 - - 
Auditory - - - - - 
Liver function - - - - - 
Renal failure - - - - - 
Sensory Neuropathy 3 - - - - 
Motor Neurpoathy - - - - - 
 
 
 
Table 5 - Drop in Creatinine Clearance, Week 5 
 1-10 
ml/min 
11-20 
ml/min 
21-30 
ml/min 
>30 
ml/min 
Drop in Creatinine 
Clearance 
18 9* - - 
* 3 patients recorded a Serum Creatinine ≥ 1.5 mg/dl, which later normalized. 
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TUMOR RESPONSE 
 
                     Overall response to therapy was 48.1% (13 patients). This included 
partial responses only, as complete responses were not seen in any of the patients 
at the time of assessment. 3 (11.1%) patients had progressive disease, and 11 
(40.8%) patients had stable disease. Patient reported improvement in symptoms 
(dysphagia relief) was seen in 85.2% of patients. This correlated with the 
achievement of partial response and/or stable disease in all these patients. 
Figures 1 to 5 illustrate the response distribution and their correlates.  
 
                      No progression was seen in 3 patients with Adenocarcinoma of 
esophagus. Relationship between pathological subtype and the type of response 
reached a 95% Confidence Interval (CI) of 0.33 (RANGE=0.33-0.5). Carcinomas 
involving the middle third esophagus did not show progression following the 
test regimen. The relationship between the site of carcinoma esophagus and type 
of response had a 95% CI of 1.02 (range: 1-1.5). Clinical benefit of therapy was 
more in high grade carcinomas than low or intermediate grade. The high grade 
tumors did not show progression after therapy, whereas 2 patients with low-
grade and 1 patient with intermediate grade cancer showed progressive disease 
(95% CI= 1, range= 0.667-1). The response rate was 52.9% in patients with loco-
regional disease and 40% in patients with metastatic (Stage IV) disease. 
Responses were observed in all sites of disease including 13 of 27 esophageal 
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lesions, 5 out of 11 patients with nodal metastasis and 4 out of 10 patients with 
metastatic disease. All the 4 patients with tracheo-esophageal fistula showed 
partial response, and there was closure of fistula in 2 patients. Among the 6 
patients with aortic infiltration, 3 showed partial response. Progression was seen 
in 3 of the 27 esophageal lesions, 2 out of 11 nodal sites and 3 out of 10 patients 
with metastatic disease.  
 
                      All 27 patients had dysphagia on study entry, 13 of whom were on 
Ryle’s tube feeding. Of the remaining 14, 9 were swallowing liquids only, 4 
swallowing soft food only, and one symptomatic on regular diet.  4 patients 
received feeding tube placement during treatment. 23 of all 27 patients (85.2%) 
experienced dysphagia relief with dose intense cisplatin, and 5-FU chemotherapy. 
The median time to dysphagia relief was 24 days (range, 4-33). Ryle’s tube 
feeding was discontinued in 13 patients by 5weeks post-therapy. Of the 23 
patients with dysphagia relief, 13 had endoscopic tumor response that was 
partial. Dysphagia relief was also observed in 11 patients who  had  no  
endoscopic response,  but whose  tumors became either  more  pliable  or  
converted from  obstructing  to  nodular,  allowing easier  passage of the 
endoscope. 
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Figure.1 
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Figure.2 
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Figure. 3 
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Figure. 4 
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Figure . 5 
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POST-PROTOCOL THERAPY UNDERGONE BY THE PATIENTS 
                        Most of the patients who were partial responders received 
multimodality treatments including surgery and/or chemoirradiation, while 
those who progressed received palliative radiotherapy, alternative chemotherapy 
or supportive care treatments. The details of post-protocol conventional 
treatments received by all the patients are in Fig. 6.  
Figure 6 
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DISCUSSION 
                      Cisplatin today is the backbone of most standard chemotherapeutic 
options in the management of esophageal carcinomas, both Squamous cell 
carcinomas and Adenocarcinomas. Most new chemotherapeutic agents have not 
remarkably improved response rates or survival, and are not affordable in 
settings with resource constraints. This study was devised to assess if increasing 
the dose intensity of the most active agent in esophageal carcinomas is feasible, 
and if it can further improve upon the clinical benefit offered by conventional 
regimens. There are very few published data on the feasibility of cisplatin dose 
intensification in esophageal carcinomas. Therefore, this study was designed to 
evaluate the feasibility, toxicity, and activity of high dose Cisplatin and 5-FU in 
patients with locally advanced and metastatic esophageal carcinomas. 
 
                        Our results demonstrate the feasibility of one course of dose intense 
cisplatin based induction chemotherapy in a carefully selected cohort of this 
population. The delivered dose intensity of 40mg/m2/week is comparable to the 
dose intensities received by esophageal, lung and ovarian cancer patients treated 
with high dose Cisplatin regimens107, 108, 109. The response proportion of 48% 
compares favorably with the response rates observed in previously mentioned 
esophageal carcinoma chemotherapy trials. In this small cohort of patients, the 
proportion of responders appeared to have been under a little influence of 
pathology (Adenocarcinoma) and location of tumor (middle third). 
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                       The question of cisplatin dosing has been addressed in other solid 
tumors with no demonstrable therapeutic benefit derived from dose escalations 
over 100 mg/m2/cycle 108. The Cisplatin dose in this trial (of one course 
induction) was effective and tolerated well. How much the subsequent cycles of 
conventional dosing would affect outcomes and toxicity needs to be evaluated 
further. Without prophylactic filgastrim, myelosuppression was high and 
resulted in febrile netropenias in 4 patients. There was no treatment related death. 
One overbearing point however is that, all the patients were inpatients during 
the treatment, and 28% required additional hospitalization on suspicion of febrile 
neutropenia or low WBC counts and evaluation of serum creatinine elevations 
≥1.5mg/dl(in 1 out of the 3patients). The cisplatin-induced nausea and emesis 
were manageable with i.v. hydration and antiemetics. Peripheral sensory 
neuropathy developed only in 3 patients (Grade-1) and was not problematic as it 
resolved within a week. 
 
                      The response rates observed in this study may be related to patient 
selection factors, to the multiday chemotherapy regimen, or to the high dose 
intensity of cisplatin. We elected to include patients with evaluable loco regional 
unresectable disease and those with measurable metastatic disease. Response in 
loco regional disease was assessed by endoscopy and CECT scan more often  
than by esophagogram(Barium swallow). Endoscopic response assessment has 
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the advantage of allowing biopsy confirmation in addition to direct tumor 
visualization. A complete endoscopic response, with the required negative 
endoscopic biopsies, however is not equivalent to a complete pathologic 
response because of sampling errors and the inability to assess extramural 
residual cancer 110. Complete endoscopic responses have been previously 
associated with improved survival in patients treated with chemoradiation111 
and are therefore clinically relevant. 13 patients in our series demonstrated 
partial responses, while none showed complete response on endoscopic 
examination after the induction treatment. 
 
                     Another focus of this study was to examine the ability of 
chemotherapy to relieve dysphagia in symptomatic patients. In this patient 
cohort, dose intense cisplatin and fluorouracil chemotherapy produced complete 
and prompt dysphagia relief in 85% of  symptomatic patients, contributing to 
improved quality of life. Complete dysphagia relief was observed both in 
patients whose primary esophageal tumors responded endoscopically and in 
those non-responders whose tumors changed in consistency or appearance. 
Presumably, the improved patency of the esophageal lumen associated with 
these tumor changes allowed easier passage of food through the cancerous 
esophageal segrnent 112. These results compare favorably to the improvement in 
dysphagia seen in 71% of patients treated with radiation alone113 and in 60-88%  
of  patients treated with concurrent chemoradiation111,114. The durability of  
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dysphagia relief due to one course of dose intense cisplatin and fluorouracil 
chemotherapy is difficult to assess because of the subsequent administration of 
radiation therapy and/or chemoradiation to patients. 
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CONCLUSIONS 
 
In conclusion, we have identified that 
 
• One course of dose intense cisplatin based chemotherapy preceding the 
standard treatment is a feasible inpatient induction treatment regimen for 
patients with locally advanced and metastatic esophageal carcinomas, and 
has an acceptable toxicity profile. 
 
• One course of dose intense cisplatin based induction chemotherapy is an 
active regimen in esophageal Squamous cell Carcinomas and 
Adenocarcinomas. In light of the high rates of dysphagia relief and clinical 
activity that is comparable to conventional chemotherapy, we believe that 
this is an effective chemotherapy regimen as an inpatient induction 
therapy. 
 
• This regimen should be considered in larger phase-II clinical studies 
evaluating induction therapy for a similar group of patients. 
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ANNEXURES 
TNM CLASSIFICATION OF  
PRIMARY ESOPHAGEAL CARCINOMA 
Primary Tumor (T) 
TX: Primary tumor cannot be assessed 
T0:  No evidence of primary tumor 
Tis: Carcinoma-in-situ 
T1:  Tumor invades lamina propria or submucosa 
T2:  Tumor invades muscularis propria 
T3:  Tumor invades adventitia 
T4: Tumor invades adjacent structures 
Regional Lymph Nodes (N) 
NX: Regional lymph nodes cannot be assessed 
N0: No regional lymph node metastasis 
N1: Regional lymph node metastasis 
DistantMetastasis (M) 
MX: Distant metastasis cannot be assessed 
M0: No distant metastasis 
M1: Distant metastasis 
Tumors of the lower thoracic esophagus 
M1a: Metastasis in celiac lymph nodes 
M1b: Other distant metastasis 
Tumors of the mid-thoracic esophagus 
M1a: Not applicable 
M1b: Non regional lymph nodes and/or otherdistant metastasis 
Tumors of the upper thoracic esophagus 
M1a: Metastasis in cervical nodes 
M1b: Other distant metastasis 
 
Stage Grouping 
Stage 0: TisN0M0 
Stage I: T1N0M0 
Stage IIA: T2N0M0 
                   T3N0M0 
Stage IIB:  T1N1M0 
                   T2N1M0 
Stage III:   T3N1M0 
                   T4AnyNM0 
Stage IV:   AnyTAnyNM1 
     Stage IVA: AnyTAnyNM1a 
     Stage IVB: AnyTAnyNM1b 
